Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Sees Significant Drop in Short Interest

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 900 shares, a drop of 10.0% from the November 15th total of 1,000 shares. Based on an average daily volume of 30,300 shares, the days-to-cover ratio is currently 0.0 days.

Emmaus Life Sciences Trading Up 93.3 %

Shares of EMMA traded up $0.01 during midday trading on Monday, hitting $0.01. The stock had a trading volume of 153,511 shares, compared to its average volume of 37,951. The business has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. The firm has a market cap of $827,064.70, a P/E ratio of -0.14 and a beta of 6.20. Emmaus Life Sciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.13.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.